Systemic and Targeted Therapies in Adenoid Cystic Carcinoma
Current Treatment Options in Oncology · 2023-01 · 24 (1) · 45-60
DOI: 10.1007/s11864-022-01043-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 13.01.2023. Verfasst von Alec J Kacew und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pritzker School of Medicine, The University of Chicago, 924 E 57th St Suite 104, Chicago, IL, 60637, USA. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 86 Literaturangaben.
Abstract (Originalsprache)
OPINION STATEMENT: Adenoid cystic carcinoma (ACC) is an often-indolent type of salivary gland cancer (SGC). A subset of patients develops progression or aggressive disease warranting systemic therapy in the recurrent/metastatic (R/M) setting. We recommend genomic testing for all patients with R/M disease to aid with prognostication and eligibility for potential experimental therapies. Here, we review the currently available treatment options (cytotoxic chemotherapies and vascular endothelial growth factor receptor (VEGFR)-targeting tyrosine kinase inhibitors (TKIs)). Based on limited data, we nominate regimens which may have more favorable efficacy profiles. Among the cytotoxic chemotherapies, several regimens are acceptable when incorporating a platinum agent. Among the VEGFR-targeting TKIs, lenvatinib and axitinib are the preferred options. Larger, randomized studies prioritizing combinations with mechanistic synergism are needed. Predictive biomarkers are critical, as there is currently little evidence to guide sequencing of available options for individual patients. Immunotherapy is an available option, but has been associated with only modest benefit in ACC. We go on to review other therapies that have been studied and nominate those with promise based on early clinical data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pritzker School of Medicine, The University of Chicago, 924 E 57th St Suite 104, Chicago, IL, 60637, USA.
- Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. glenn_hanna@dfci.harvard.edu.
Zitieren
APA
Kacew, A. J., & Hanna, G. J. (2023). Systemic and Targeted Therapies in Adenoid Cystic Carcinoma. Current Treatment Options in Oncology, 24(1), 45-60. https://doi.org/10.1007/s11864-022-01043-2
Vancouver
Kacew AJ, Hanna GJ. Systemic and Targeted Therapies in Adenoid Cystic Carcinoma. Current Treatment Options in Oncology. 2023;24(1):45-60. doi:10.1007/s11864-022-01043-2
BibTeX
@article{Kacew2023,
author = {Kacew, Alec J and Hanna, Glenn J},
title = {Systemic and Targeted Therapies in Adenoid Cystic Carcinoma},
journal = {Current Treatment Options in Oncology},
year = {2023},
volume = {24},
number = {1},
pages = {45--60},
doi = {10.1007/s11864-022-01043-2}
}
EUVIMED